Searched for
NOVEL THERAPEUTICS
Wockhardt secures US FDA approval for antibiotic ZaynichWockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. Thi...- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Quote of the day by Anne Rice: 'You do have a story inside you; it lies articulate and waiting to be written — behind your silence and your suffering' ; life lessons from American literary iconAnne Rice's quote, "You do have a story inside you; it lies articulate and waiting to be written — behind your silence and your suffering,"...
- Kiran Mazumdar-Shaw picks niece Claire as successor at BioconBiocon's founder Kiran Mazumdar-Shaw has made a groundbreaking announcement, pledging her niece Claire Mazumdar as her heir apparent. The t...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- Claire Mazumdar: A silent force behind a $1.6 billion firm may write Biocon's future scriptsBiocon founder Kiran Mazumdar-Shaw has named her niece, Claire Mazumdar, as her successor. Claire Mazumdar, a successful CEO of Bicara Ther...
- Amazon launches AI research tool to speed early-stage drug discoveryAmazon Web Services has launched Amazon Bio Discovery, an AI tool to accelerate drug discovery. Scientists can now generate and evaluate po...
- Mounjaro maker signs $2.7 billion deal on AI drug researchThe new deal builds on existing collaborations between the two companies, which struck a software licensing agreement in 2023, according to...
- Jubilant Pharmova names Daniel J O'Connor as CEO of proprietary drugs bizJubilant Pharmova has appointed Daniel J O'Connor as the CEO of its novel drugs business. O'Connor brings over 30 years of leadership exper...
- Godavari Biorefineries secures Chinese patent for breakthrough anti-cancer moleculeGodavari Biorefineries received a patent from China for its new anti-cancer molecule. The China National Intellectual Property Administrati...
- Healthcare startups showcase innovation, collaboration at Bengaluru Tech Summit 2024The panel included several young entrepreneurs in the healthcare industry, sharing their perspectives on a range of topics. They discussed ...
- Centre of Excellence at IIT Madras to develop biomarkers for early detection of pancreatic cancerThe Indian Institute of Technology (IIT), Madras has set up a Centre of Excellence to develop biomarkers for early detection of pancreatic ...
- Cellogen to bring next-gen cancer therapy to India"Chimeric Antigen Receptor cells represent a cutting-edge technology that holds great promise for cancer treatment. We are delighted to off...
- Oscar winner Charlize Theron joins Andy and Barbara Muschietti to develop 'Final Girl Support Group' seriesThe TV series is set up at the streaming platform HBO Max and Andy Muschietti, known for helming the 'It' horror films.
- Biocon shares soar 12 pc as co inks pact with Quark PharmaBiocon's scrip ended the day at Rs 437.35, a gain of 11.38% on the BSE. During the day, the scrip surged 14.83% to Rs 450.90 -- its 52-week...
- Biocon inks licensing pact with US-based Quark PharmaBiocon today said it has inked a pact with Quark Pharmaceuticals, Inc to develop a range of siRNA (small interfering RNA) based novel thera...
- Novel therapyAs he scribbled away to crank up masterpieces such as La Comédie humaine, French novelist and playwright Honoré de Balzac consumed prodigio...
- Biocon unit inks pact with US firm to expand collaborationBiotech firm Biocon today said its subsidiary 'Syngene International' has entered into an agreement with US-based Endo Pharmaceuticals to e...
- Piramal Life Sciences mulls Rs 200 cr investment in R&DPiramal Life Sciences, R&D arm of Piramal Group, is investing Rs 200 crore in next two year's period for its ambitious programme to discove...
Load More
